Glucagon-like peptide-1 receptor agonist prescribing patterns in adolescents with type 2 diabetes

Diabetes Obes Metab. 2022 Jul;24(7):1380-1384. doi: 10.1111/dom.14681. Epub 2022 May 1.

Authors

Megan O Bensignor¹, Jack M Wolf², Kyle D Rudser², Aaron S Kelly¹, Silva Arslanian³

Affiliations

¹ Center for Pediatric Obesity Medicine, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA.
² Division of Biostatistics, University of Minnesota, Minneapolis, Minnesota, USA.
³ Center for Pediatric Research in Obesity and Metabolism, Division of Pediatric Endocrinology and Metabolism, UPMC Children's Hospital, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

No abstract available

Keywords: GLP-1 analogue; antidiabetic drug; exenatide; liraglutide; type 2 diabetes.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Adolescent
Diabetes Mellitus, Type 2* / drug therapy
Glucagon-Like Peptide-1 Receptor / agonists
Humans
Hypoglycemic Agents / therapeutic use
Liraglutide
Venoms

Substances

Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents
Venoms
Liraglutide

Grants and funding